Surprisingly, in most patients, R-2-HG levels remained suppressed at relapse, indicating that disease recurrence was not relying on IDH2 mutant activity; moreover, RTK pathway genes mutations were not associated with acquired resistance in this group of patients with IDH2-mutated R/R AML (52). The gene discussed is IDH2; the disease is acute myeloid leukemia.